000			01426 a2200241 4500
999			_c2350 _d2350
003			OSt
005			20191226214905.0
008
020			_a 9241546417
060		4	_aQV 77.2 I 2005
245	0	0	_aImproving access and use of psychotropic medicines.
260			_aGeneva : _bWorld Health Organization, _c2005.
300			_axi, 57 p. : _bill. ; _c29 cm.
520			_aThe objective of this document is to provide guidance to risk assessors on the use of quantitative toxicokinetic and toxicodynamic data to address interspecies and interindividual differences in dose/concentration-response assessment. Section 1 focuses on the relevance of this guidance in the context of the broader risk assessment paradigm and other initiatives of the International Program on Chemical Safety (IPCS) project on the Harmonization of Approaches to the Assessment of Risk from Exposure to Chemicals. Technical background material is presented in section 2, followed by generic guidance for the development of chemical-specific adjustment factors in section 3 and accompanying summary figures. Illustrative case-studies are included in an Appendix and a glossary of terms is also provided.
650	0	2	_aPsychotropic drugs
650	0	2	_aEssential drugs
650	0	2	_aMental disorders
650	0	2	_aDrug utilization.
650	0	2	_aDrug costs. _97079
650	0	2	_aDrug and narcotic control
650	0	2	_aGuidelines.
942			_2NLM _cBK